TY - JOUR
T1 - The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments
T2 - Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
AU - Tur, Carmen
AU - Dubessy, Anne Laure
AU - Otero-Romero, Susana
AU - Amato, Maria Pia
AU - Derfuss, Tobias
AU - Di Pauli, Franziska
AU - Iacobaeus, Ellen
AU - Mycko, Marcin
AU - Abboud, Hesham
AU - Achiron, Anat
AU - Bellinvia, Angelo
AU - Boyko, Alexey
AU - Casanova, Jean Laurent
AU - Clifford, David
AU - Dobson, Ruth
AU - Farez, Mauricio F.
AU - Filippi, Massimo
AU - Fitzgerald, Kathryn C.
AU - Fonderico, Mattia
AU - Gouider, Riadh
AU - Hacohen, Yael
AU - Hellwig, Kerstin
AU - Hemmer, Bernhard
AU - Kappos, Ludwig
AU - Ladeira, Filipa
AU - Lebrun-Frénay, Christine
AU - Louapre, Céline
AU - Magyari, Melinda
AU - Mehling, Matthias
AU - Oreja-Guevara, Celia
AU - Pandit, Lekha
AU - Papeix, Caroline
AU - Piehl, Fredrik
AU - Portaccio, Emilio
AU - Ruiz-Camps, Isabel
AU - Selmaj, Krzysztof
AU - Simpson-Yap, Steve
AU - Siva, Aksel
AU - Sorensen, Per Soelberg
AU - Sormani, Maria Pia
AU - Trojano, Maria
AU - Vaknin-Dembinsky, Adi
AU - Vukusic, Sandra
AU - Weinshenker, Brian
AU - Wiendl, Heinz
AU - Winkelmann, Alexander
AU - Zuluaga Rodas, María Isabel
AU - Tintoré, Mar
AU - Stankoff, Bruno
N1 - Funding Information:
45. H.W. receives honoraria for acting as a member of Scientific Advisory Boards Biogen, Genzyme, Merck Serono, Novartis, Roche Pharma AG, and Sanofi Aventis, UCB as well as speaker honoraria and travel support from Alexion, Biogen, Biologix, Cognomed, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, Merck, Novartis, Roche Pharma AG, Genzyme, TEVA, and WebMD Global. Professor H.W. is acting as a paid consultant for Actelion, Argenx, Biogen, Bristol Myers Squibb, EMD Serono, Idorsia, IGES, Immunic, Immunovant, Janssen, Johnson & Johnson, Novartis, Roche, Sanofi, the Swiss Multiple Sclerosis Society, and UCB and research funding by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, the European Union, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and Biogen, GlaxoSmithKline, Roche Pharma AG, Sanofi Genzyme, outside the submitted work.
Funding Information:
8. M.M. has been supported by the National Science Centre Poland grant no. 2020/01/0/NZ6/00072.
Funding Information:
43. S.V. received grants, personal fees, and non-financial support from Biogen, grants and personal fees from Celgene, grants, personal fees, and non-financial support from Genzyme, grants, personal fees and non-financial support from Merck Serono, grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from Roche, grants, personal fees, and non-financial support from Sanofi.
Funding Information:
5. T.D. serves on scientific advisory boards for Novartis, Merck, Biogen, Genzyme, GeNeuro, Mitsubishi Pharma, Actelion, Roche, Alexion, and Celgene; has received funding for travel and/or speaker honoraria from Biogen, Genzyme, Novartis, Merck, and Roche; and received research support from Alexion, Biogen, Novartis, Roche, the European Union, the Swiss National Science Foundation, and the Swiss MS Society.
Funding Information:
1. C.T. is currently being funded by a Junior Leader La Caixa Fellowship (fellowship code is LCF/BQ/PI20/11760008), awarded by “la Caixa” Foundation (ID 100010434). She has also received the 2021 Merck’s Award for the Investigation in MS, awarded by Fundación Merck Salud (Spain). In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She has also received honoraria from Roche and Novartis, and is a steering committee member of the of the O’HAND trial and of the Consensus group on Follow-on DMTs. She is a member of the Editorial Boards of Neurology and Multiple Sclerosis Journal. Dr C.T. has no disclosures related to this work.
Funding Information:
40. M.P.S. has received consulting fees and research grants from Biogen, Roche, Novartis, Sanofi, Merck, GSK, Immunic, and GeNeuro.
Funding Information:
38. A.S. has received honoraria or consultancy fees for participating to advisory boards, giving educational lectures and/or travel and registration coverage for attending scientific congresses or symposia from F. Hoffmann-La Roche Ltd., Sanofi Genzyme, Merck Serono, Novartis, Teva, Biogen Idec/Gen Pharma of Turkey, and Abdi İbrahim İlaç. He reports getting research grants from Istanbul University Research Support Grants, and from The Scientific and Technological Research Council Of Turkey—Health Sciences Research Grants. Dr A.S. has no disclosures related to this work.
Funding Information:
41. M.T. has received compensation for consulting from Biogen, Genzyme, Merck Serono, Novartis, and Roche and speaker honoraria from Biogen, Genzyme, Merck Serono, Novartis, Sanofi, and Teva, and her institution has received research grants from Biogen, Merck Serono, and Novartis.
Funding Information:
6. F.D.P. has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations), or travel funding from Bayer, Biogen, Celgene, Merck, Novartis, Sanofi Genzyme, Roche, and Teva.
Publisher Copyright:
© The Author(s), 2022.
PY - 2022/8
Y1 - 2022/8
N2 - Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
AB - Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
KW - coronavirus disease 2019
KW - COVID-19
KW - disease-modifying treatment
KW - DMT-associated infections
KW - Multiple sclerosis
KW - neuromyelitis optica spectrum disorder
KW - progressive multifocal leukoencephalopathy
KW - risk mitigation strategies
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85134083277&partnerID=8YFLogxK
U2 - 10.1177/13524585211069068
DO - 10.1177/13524585211069068
M3 - Article
C2 - 35196927
AN - SCOPUS:85134083277
SN - 1352-4585
VL - 28
SP - 1424
EP - 1456
JO - Multiple Sclerosis
JF - Multiple Sclerosis
IS - 9
ER -